Related Experiment Video
Updated: Apr 6, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study
Abstract:
Noninvasive imaging is a critical technology for diagnosis, classification, and subsequent treatment planning for patients with glioblastoma. It has been shown that the EphA2 receptor tyrosine kinase (RTK) is overexpressed in a number of tumors, including glioblastoma. Expression levels of Eph RTKs have been linked to tumor progression, metastatic spread, and poor patient prognosis. As EphA2 is expressed at low levels in normal neural tissues, this protein represents an attractive imaging target for delineation of tumor infiltration, providing an improved platform for image-guided therapy. In this study, EphA2-4B3, a monoclonal antibody specific to human EphA2, was labeled with 64Cu through conjugation to the chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). The resulting complex was used as a positron emission tomography (PET) tracer for the acquisition of high-resolution longitudinal PET/magnetic resonance images. EphA2-4B3-NOTA-64Cu images were qualitatively and quantitatively compared to the current clinical standards of [18F]FDOPA and gadolinium (Gd) contrast-enhanced MRI. We show that EphA2-4B3-NOTA-64Cu effectively delineates tumor boundaries in three different mouse models of glioblastoma. Tumor to brain contrast is significantly higher in EphA2-4B3-NOTA-64Cu images than in [18F]FDOPA images and Gd contrast-enhanced MRI. Furthermore, we show that nonspecific uptake in the liver and spleen can be effectively blocked by a dose of nonspecific (isotype control) IgG.
Insights
A novel positron emission tomography (PET) tracer targeting EphA2 receptor tyrosine kinase (RTK) shows improved glioblastoma imaging. This new tracer offers higher tumor-to-brain contrast than current methods for better image-guided therapy.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Noninvasive imaging is crucial for glioblastoma diagnosis and treatment planning.
- EphA2 receptor tyrosine kinase (RTK) is overexpressed in glioblastoma, making it a potential imaging target.
- EphA2's low expression in normal brain tissue enhances its utility for delineating tumor infiltration.
Purpose of the Study:
- To develop and evaluate a novel positron emission tomography (PET) tracer for imaging glioblastoma.
- To assess the efficacy of the EphA2-targeting tracer compared to current clinical imaging standards.
- To improve image-guided therapy for glioblastoma patients.
Main Methods:
- A monoclonal antibody (EphA2-4B3) specific to human EphA2 was labeled with 64Cu using NOTA.
- The resulting EphA2-4B3-NOTA-64Cu complex was used as a PET tracer.
- PET/magnetic resonance imaging (MRI) was performed in three glioblastoma mouse models and compared with [18F]FDOPA and Gd-enhanced MRI.
Main Results:
- EphA2-4B3-NOTA-64Cu effectively delineated tumor boundaries in glioblastoma models.
- The tracer demonstrated significantly higher tumor-to-brain contrast compared to [18F]FDOPA and Gd-enhanced MRI.
- Nonspecific uptake in liver and spleen was successfully blocked using an isotype control IgG.
Conclusions:
- EphA2-4B3-NOTA-64Cu is a promising PET tracer for high-contrast glioblastoma imaging.
- This tracer offers potential for improved delineation of tumor infiltration and image-guided therapy.
- Targeting EphA2 provides a valuable strategy for enhancing glioblastoma visualization.
More Related Videos
Related Concept Videos
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET